Literature DB >> 20154038

Association between hypoparathyroidism and defective T cell immunity in 22q11.2 deletion syndrome.

A Herwadkar1, A R Gennery, A S Moran, M R Haeney, P D Arkwright.   

Abstract

AIMS: Although poor thymic function leading to viral and fungal infections can be a feature of chromosome 22q11.2 deletion syndrome, most patients have relatively normal immunity. The aim of this study was to investigate which clinical and laboratory parameters best predict the likelihood of serious or recurrent infections in patients with this syndrome.
METHODS: Clinical and laboratory parameters from 64 patients with 22q11.2 deletion syndrome referred to two immunology centres in the north of England were studied retrospectively.
RESULTS: 31 (48%) patients had no problems with infection, 21 (33%) had bacterial infections, and 12 (19%) had recurrent or persistent thrush and/or viral enteritis and bronchiolitis, the latter suggestive of a significant T cell immunodeficiency. Patients with a history of thrush/viral infections, but not those with bacterial infections, had significantly lower CD4+ and CD8+ T lymphocyte numbers (relative risk (95% CI) 0.3 (0.1 to 0.8)) and phytohaemagglutinin mitogen responses (0.4 (0.2 to 0.8)) adjusted for age at testing. Hypoparathyroidism was associated with low T lymphocyte numbers and function (p<0.05) as well as an increased risk of thrush/viral infections (p<0.0001) after adjusting for age at testing.
CONCLUSIONS: 22q11.2 syndrome patients with hypoparathyroidism are more likely to have a clinically significant T cell immunodeficiency and lower laboratory parameters of T cell function, with a higher risk of thrush and viral bronchiolitis and enteritis. Measurement of absolute CD3 count is a simple and accurate predictor of fungal/viral infection risk, with phytohaemagglutinin mitogen responses providing little or no further value in most patients.

Entities:  

Mesh:

Year:  2010        PMID: 20154038     DOI: 10.1136/jcp.2009.072074

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome.

Authors:  Yiwa Suksawat; Achara Sathienkijkanchai; Jittima Veskitkul; Orathai Jirapongsananuruk; Nualanong Visitsunthorn; Pakit Vichyanond; Punchama Pacharn
Journal:  J Clin Immunol       Date:  2017-04-20       Impact factor: 8.317

Review 2.  Immunological aspects of 22q11.2 deletion syndrome.

Authors:  A R Gennery
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

Review 3.  Hypocalcemia: updates in diagnosis and management for primary care.

Authors:  Jeremy Fong; Aliya Khan
Journal:  Can Fam Physician       Date:  2012-02       Impact factor: 3.275

4.  Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome.

Authors:  Jenny Lingman Framme; Stephan Borte; Ulrika von Döbeln; Lennart Hammarström; Sólveig Oskarsdóttir
Journal:  J Clin Immunol       Date:  2014-03-09       Impact factor: 8.317

Review 5.  Immune and Genetic Features of the Chromosome 22q11.2 Deletion (DiGeorge Syndrome).

Authors:  Caroline Y Kuo; Rebecca Signer; Sulagna C Saitta
Journal:  Curr Allergy Asthma Rep       Date:  2018-10-30       Impact factor: 4.806

Review 6.  Variable immune deficiency related to deletion size in chromosome 22q11.2 deletion syndrome.

Authors:  Blaine Crowley; Melanie Ruffner; Donna M McDonald McGinn; Kathleen E Sullivan
Journal:  Am J Med Genet A       Date:  2018-01-17       Impact factor: 2.802

Review 7.  Inborn errors of thymic stromal cell development and function.

Authors:  Alexandra Y Kreins; Stefano Maio; Fatima Dhalla
Journal:  Semin Immunopathol       Date:  2020-11-30       Impact factor: 9.623

Review 8.  Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete Athymia.

Authors:  E Graham Davies
Journal:  Front Immunol       Date:  2013-10-31       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.